WO2004037843A3 - Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments - Google Patents

Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments Download PDF

Info

Publication number
WO2004037843A3
WO2004037843A3 PCT/IL2003/000878 IL0300878W WO2004037843A3 WO 2004037843 A3 WO2004037843 A3 WO 2004037843A3 IL 0300878 W IL0300878 W IL 0300878W WO 2004037843 A3 WO2004037843 A3 WO 2004037843A3
Authority
WO
WIPO (PCT)
Prior art keywords
groups
medicaments
preparation
nitric oxide
superoxide dismutase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2003/000878
Other languages
French (fr)
Other versions
WO2004037843A2 (en
Inventor
Abdullah Ibrahim Haj-Yehia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Priority to US10/532,390 priority Critical patent/US20060247216A1/en
Priority to EP03769864A priority patent/EP1562975A2/en
Priority to AU2003278565A priority patent/AU2003278565A1/en
Publication of WO2004037843A2 publication Critical patent/WO2004037843A2/en
Publication of WO2004037843A3 publication Critical patent/WO2004037843A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to multifunctional steroid compounds combining a steroid component with SOD mimic component and optionally also with NO donor component, and to their use in treating and preventing disorders associated with oxidative stress and free radical injury, or disorders in which treatment with steroids is indicated, whereas such combination increases the efficacy of treatment and reduces side effects associated with steroid treatment. The invention further relates to methods and devices for administering the compounds.
PCT/IL2003/000878 2002-10-25 2003-10-24 Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments Ceased WO2004037843A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/532,390 US20060247216A1 (en) 2002-10-25 2003-10-24 Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
EP03769864A EP1562975A2 (en) 2002-10-25 2003-10-24 Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
AU2003278565A AU2003278565A1 (en) 2002-10-25 2003-10-24 Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42127202P 2002-10-25 2002-10-25
US60/421,272 2002-10-25

Publications (2)

Publication Number Publication Date
WO2004037843A2 WO2004037843A2 (en) 2004-05-06
WO2004037843A3 true WO2004037843A3 (en) 2004-06-10

Family

ID=32176692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000878 Ceased WO2004037843A2 (en) 2002-10-25 2003-10-24 Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments

Country Status (4)

Country Link
US (1) US20060247216A1 (en)
EP (1) EP1562975A2 (en)
AU (1) AU2003278565A1 (en)
WO (1) WO2004037843A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030743A1 (en) * 2003-04-11 2004-10-12 Biopeg Ltd POLYETHYLENGLYCULATED DERIVATIVES THAT RELEASE NITRIC OXIDE.
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (en) 2011-11-23 2021-09-30 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (en) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. NATURAL COMBINED HORMONE SUBSTITUTION COMPOSITIONS AND THERAPIES
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3696185A1 (en) * 2015-11-12 2020-08-19 Board of Regents of the University of Nebraska Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US12473326B2 (en) 2019-02-01 2025-11-18 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
CN114599406A (en) * 2019-07-10 2022-06-07 波纹疗法公司 Surface coatings and implantable devices comprising binary steroid prodrugs and uses thereof
US20220347305A1 (en) 2019-08-07 2022-11-03 Ripple Therapeutics Corporation Controlled release drug dimers
KR102240928B1 (en) * 2019-12-19 2021-04-14 디어젠 주식회사 Pharmaceutical composition for prevention or treatment of central nervous system diseases by TDP-43 mediated stress granule aggregation in cells via inhibiting ATXN2
WO2022203097A1 (en) * 2021-03-24 2022-09-29 디어젠 주식회사 Composition, for preventing and treating central nervous system disorders, inhibiting overproduction of tdp-43 proteins by controlling atxn2 which is stress granule controller
CN117801047B (en) * 2023-01-19 2024-12-20 北京华睿鼎信科技有限公司 Neurosteroid derivative and use thereof
CN118924767B (en) * 2024-07-25 2025-11-11 中南大学湘雅医院 Use of pregnenolone as active ingredient in preparation of medicine for treating psoriasis or atopic dermatitis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3014932A (en) * 1957-07-20 1961-12-26 Syntex Sa 6-nitro steroids
US3054812A (en) * 1960-12-02 1962-09-18 Roussel Uclaf 20beta, 21-dinitrato-delta4-pregnene-17alpha-ol-3, 11-dione, its production, and method of use
US3215713A (en) * 1960-04-04 1965-11-02 Schering Corp Steroid nitrite esters
US5707984A (en) * 1995-12-08 1998-01-13 G. D. Searle & Co. Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
US5750744A (en) * 1994-05-02 1998-05-12 Merrell Pharmaceuticals Inc. Process for the preparation of 4-amino- 4-3-ketosteroids via 4-nitro- 4-3-ketosteroids
US5985862A (en) * 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
WO2000049993A2 (en) * 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2437261A (en) * 1944-10-09 1948-03-09 Cons Royal Chemical Corp Condensation products of cholesteryl esters with polyethylene glycol and process for producing same
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
EP0470154B1 (en) * 1989-04-28 1996-06-05 Riker Laboratories, Inc. Dry powder inhalation device
WO1991009596A1 (en) * 1990-01-05 1991-07-11 Sepracor, Inc. Optically pure r(-) albuterol for treating asthma
US5364833A (en) * 1990-05-09 1994-11-15 Basf Aktiengesellschaft Cyclohexenone oxime ethers, their preparation and their use as herbicides
US5404871A (en) * 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US6299863B1 (en) * 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5492112A (en) * 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6060069A (en) * 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US5821259A (en) * 1991-11-12 1998-10-13 Theoharides; Theoharis C. H3 -receptor agonists as therapeutic agents
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US5277195A (en) * 1992-02-03 1994-01-11 Dura Pharmaceuticals, Inc. Portable spirometer
DE69322789T2 (en) * 1992-10-19 1999-07-01 Dura Pharmaceuticals, Inc., San Diego, Calif. DRY POWDER INHALATOR
IT1256450B (en) * 1992-11-26 1995-12-05 Soldato Piero Del NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION
WO1994016756A1 (en) * 1993-01-29 1994-08-04 Miris Medical Corporation Intrapulmonary delivery of hormones
US5558085A (en) * 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5672581A (en) * 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5364838A (en) * 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5743250A (en) * 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5661130A (en) * 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
WO1995009831A1 (en) * 1993-10-06 1995-04-13 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
US6255296B1 (en) * 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
JP4043046B2 (en) * 1994-05-10 2008-02-06 ニコックス エス エイ Nitro compounds having anti-inflammatory, analgesic and antithrombotic activity and compositions thereof
PT758890E (en) * 1994-05-11 2005-06-30 Jes Olesen USE OF CATCH AGENTS, INHIBITORS OR ANTAGONISTS OF NO IN THE TREATMENT OF ENXAQUECA
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5645051A (en) * 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) * 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5610149A (en) * 1995-05-12 1997-03-11 The Research Foundation Of State University Of New York Steroidal polyamines
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5916900A (en) * 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
IT1276071B1 (en) * 1995-10-31 1997-10-24 Nicox Ltd ANTI-INFLAMMATORY ACTIVITY COMPOSITES
JP2002515863A (en) * 1996-01-25 2002-05-28 ウィリアム ビー ウェグリッキ Intravenous magnesium gluconate for treating symptoms caused by excessive oxidative stress due to free radical distribution
US6121309A (en) * 1996-03-18 2000-09-19 Eisai Co., Ltd. Fused-ring carboxylic acid derivatives
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
EP1021430A1 (en) * 1996-07-19 2000-07-26 Centaur Pharmaceuticals, Inc. Furan nitrone compounds
CA2231879C (en) * 1996-07-22 2007-01-23 Suntory Limited Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same
IT1295694B1 (en) * 1996-11-14 1999-05-27 Nicox Sa NITROXIS DERIVATIVES FOR THE PREPARATION OF MEDICATIONS WITH ANTI-THROMBINIC ACTIVITY
AU742388B2 (en) * 1996-12-24 2002-01-03 Chugai Seiyaku Kabushiki Kaisha Aromatic amine derivatives having nos inhibiting action
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
IL120531A (en) * 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
IT1292377B1 (en) * 1997-06-19 1999-02-08 Nicox Sa PROSTAGLANDINE PHARMACEUTICAL COMPOSITIONS
IT1292426B1 (en) * 1997-06-27 1999-02-08 Nicox Sa NITRATED SALTS OF ACE-INHIBITORS
US6254882B1 (en) * 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
US6440961B1 (en) * 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
GB9801398D0 (en) * 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
IN188837B (en) * 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
GB9811599D0 (en) * 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
MXPA00012808A (en) * 1998-06-22 2002-04-24 American Biogenetic Sciences The use of valproic acid analog for the treatment and prevention of migraine and affective illness.
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US6376550B1 (en) * 1999-02-09 2002-04-23 Asta Medica Ag Pharmaceutical compositions containing tramadol for migraine
CO5150225A1 (en) * 1999-03-19 2002-04-29 Merck Sharp & Dohme DERIVATIVES OF TETRAHYDROPIRANE AND ITS USE AS THERAPEUTIC AGENTS
AU4841700A (en) * 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US6429219B1 (en) * 1999-05-25 2002-08-06 Chronorx, Llc Treatment of chronic hypertension and related conditions with thiol complexes
US7678364B2 (en) * 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6414505B1 (en) * 1999-11-03 2002-07-02 Compaq Information Technologies Group, L.P. Multiboard run-in tester for PCI expansions
WO2001051030A1 (en) * 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3014932A (en) * 1957-07-20 1961-12-26 Syntex Sa 6-nitro steroids
US3215713A (en) * 1960-04-04 1965-11-02 Schering Corp Steroid nitrite esters
US3054812A (en) * 1960-12-02 1962-09-18 Roussel Uclaf 20beta, 21-dinitrato-delta4-pregnene-17alpha-ol-3, 11-dione, its production, and method of use
US5750744A (en) * 1994-05-02 1998-05-12 Merrell Pharmaceuticals Inc. Process for the preparation of 4-amino- 4-3-ketosteroids via 4-nitro- 4-3-ketosteroids
US5707984A (en) * 1995-12-08 1998-01-13 G. D. Searle & Co. Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
US5985862A (en) * 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
WO2000049993A2 (en) * 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DJERBASSI ET AL.: "Reaction of Steroidal Sapogenin Spiroketal with Ethanediol", J. ORG. CHEM., vol. 24, no. 1, 3 February 1959 (1959-02-03), pages 1 - 6, XP002275443 *
HIRSCH A.F. ET AL: "Contagestational Agents. 1. Steroidal O-Aryloximes", J. MEDICINAL CHEMISTRY, vol. 20, no. 12, 1977, pages 1546 - 1551, XP002275447 *
JONES, J. BRYAN AND GORDON, KEITH D.: "Micellar Aggregation and delat5-3-Keto Steroids Lacking a Polar C-17 Group and Its Relation to the Activity and Specificity of the delta5 to delta4-3-Ketosteroid Isomerase of Pseudomonas testosteroni", BIOCHEMISTRY, VOL. 12, NO. 1, 1973, vol. 12, no. 1, 1973, pages 71 - 76, XP002275445 *
KEANA, JOHN F. W. ET AL: "Synthesis of a novel cholesterol nitric oxide spin label. Application to the molecular organisation of human high density lipoprotein", J. AMER. CHEM.SOC, vol. 103, no. 16, 1981, pages 4904 - 4912, XP002275442 *
SONDHEIMER F. ET AL.: "Steroids. LXVII. The Decarboxylation of Unsaturated Steroidal Acids. Synthesis of 17-Epitestosterone and 17-methylepitestosterone", J. AMER. CHEM. SOC, vol. 77, 1955, pages 4145 - 4149, XP002275444 *
TSUJI, NATSUKO ET AL.: "Highly Stereoselective Hydrogenation of 3-oxo-4-ene and 1,4-diene Steroids to 5-beta Compounds with Palladium Catalyst", J. ORG. CHEM, vol. 45, 1980, pages 2729 - 2731, XP002275446 *
ZE'EV ZARETSKII AND L. KELNER: "Mass Spectrometry of Steroid Systems-XXII", TETRAHEDRON, vol. 31, 1975, pages 85 - 87, XP002275441 *

Also Published As

Publication number Publication date
AU2003278565A8 (en) 2004-05-13
EP1562975A2 (en) 2005-08-17
WO2004037843A2 (en) 2004-05-06
AU2003278565A1 (en) 2004-05-13
US20060247216A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2005000217A3 (en) Combination therapy for the treatment of dyslipidemia
WO2005027842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
WO2002044187A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
WO2004110368A3 (en) Combination therapy for the treatment of hypertension
WO2002069963A3 (en) Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
WO2005070052A3 (en) Use of photodynamic therapy to enhance treatment with immuno-modulating agents
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2004064734A3 (en) Combination therapies for the treatment of cancer
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
WO2005112634A3 (en) Medical treatment kit and methods of use thereof
WO2000049993A3 (en) Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
WO2004087212A3 (en) Nitric oxide in treatment of inflammation
WO2004093995A3 (en) Use of antioxidants to treat bone loss disorders
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
WO2002009683A3 (en) Aldosterone blocker therapy to prevent or treat inflammation-related disorders
WO2003097050A3 (en) A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
AU2003278434A1 (en) Cardiovascular protection using anti-aldosteronic progestins
TW200511996A (en) The use of steroids to treat persons suffering from ocular disorders
WO2005094554A3 (en) Therapeutic agents, methods, and treatments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003769864

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003769864

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006247216

Country of ref document: US

Ref document number: 10532390

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10532390

Country of ref document: US